GNTA
Genenta Science·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
GNTA Profile
Genenta Science S.P.A.
A biotech company that developing hematopoietic stem cell fund therapies for solid tumors
Biological Technology
--
12/15/2021
NASDAQ Stock Exchange
13
12-31
Depository Receipts (Ordinary Shares)
Via Olgettina No. 58, 20132 Milan, Italy
--
Genenta Science S.p.A. is established under the laws of the Italian Republic. The company is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors. The Company has developed a novel biological platform that involves the transfer of in vitro genes of treatment candidates into autologous hematopoietic stem/progenitor cells (" HSPCs ") to deliver immunomodulatory molecules directly to tumors by infiltrating monocytes/macrophages (Tie 2 Expressing Monocytes – "TEMs "). The company's technology aims to turn TEMs, which usually have an affinity for tumors and spread to tumors, into "Trojan horses" to fight cancer progression and prevent tumor recurrence.
